WallStSmart

Microbot Medical Inc (MBOT)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 10850189% more annual revenue ($37.54B vs $346,000). MDT leads profitability with a 13.9% profit margin vs 0.0%. MBOT appears more attractively valued with a PEG of 0.70. MDT earns a higher WallStSmart Score of 68/100 (B-).

MBOT

Avoid

34

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 7.0Quality: 8.5
Piotroski: 3/9Altman Z: 10.47

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MBOTUndervalued (+25.1%)

Margin of Safety

+25.1%

Fair Value

$2.67

Current Price

$1.45

$1.22 discount

UndervaluedFair: $2.67Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MBOT4 strengths · Avg: 9.5/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
10.4710/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.708/10

Growing faster than its price suggests

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

MBOT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$98.06M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MBOT

The strongest argument for MBOT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.70 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : MBOT

The primary concerns for MBOT are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

MBOT carries more volatility with a beta of 1.03 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 34/100) and 13.7% revenue growth. MBOT offers better value entry with a 25.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Microbot Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery space. The company is headquartered in Hingham, Massachusetts.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?